Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder

Part of paid clinical trials in Albuquerque, New Mexico.

Sponsor
University of New Mexico
Study ID
NCT07506395
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 89 Years
Healthy Volunteers
Not accepted

Interventions

  • Psilocybin — DRUG
    Two group-format dosing sessions, scheduled 4 weeks apart, will be held at the ISUBI Center at UNM or a site outside of UNM with DEA approval for psilocybin storage

Study Details

This study is a community-informed, pragmatic, open-label, phase 1 clinical trial of group-format psilocybin-assisted therapy (GPAT) for individuals with post-traumatic stress disorder (PTSD). The primary objectives of this phase 1 study are to assess the safety and feasibility of (GPAT) for individuals with (PTSD) and to evaluate preliminary effects on PTSD severity.

Key Dates

Start date
May 1, 2026
Status verified
May 2026
Primary completion
May 1, 2027
Completion
May 1, 2028

Study Design

Enrollment
36 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: GPAT-PTSD

Primary Outcome Measure

Rate of study completion-feasabiity measure [ Time Frame: 18 weeks after baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Interdisciplinary Substance Use and Brain Injury (ISUBI)AlbuquerqueNew Mexico87131
Victoria Culkin, MA
[email protected]
505-272-1754
Victoria Culkin, MA
[email protected]

Find similar trials in Albuquerque, NM

By condition
PTSD (post-traumatic stress disorder)
By specialty
PsychiatryMental healthBehavioral health
By research site
Interdisciplinary Substance Use and Brain Injury (ISUBI)· Albuquerque, NM

Related Studies